Elizabeth A. Sugar

11.9k total citations · 1 hit paper
113 papers, 6.2k citations indexed

About

Elizabeth A. Sugar is a scholar working on Oncology, Ophthalmology and Epidemiology. According to data from OpenAlex, Elizabeth A. Sugar has authored 113 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 23 papers in Ophthalmology and 22 papers in Epidemiology. Recurrent topics in Elizabeth A. Sugar's work include Pancreatic and Hepatic Oncology Research (25 papers), Ocular Diseases and Behçet’s Syndrome (23 papers) and Retinal and Optic Conditions (16 papers). Elizabeth A. Sugar is often cited by papers focused on Pancreatic and Hepatic Oncology Research (25 papers), Ocular Diseases and Behçet’s Syndrome (23 papers) and Retinal and Optic Conditions (16 papers). Elizabeth A. Sugar collaborates with scholars based in United States, United Kingdom and Australia. Elizabeth A. Sugar's co-authors include Gypsyamber DʼSouza, Maura L. Gillison, Raphael P. Viscidi, Weihong Xiao, Shahnaz Begum, William H. Westra, Janet T. Holbrook, Douglas A. Jabs, Elizabeth M. Jaffee and Michael M. Altaweel and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Blood.

In The Last Decade

Elizabeth A. Sugar

110 papers receiving 6.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Distinct Risk Factor Profiles for Human Papillomavirus Type 16–Positive and Human Papillomavirus Type 16–Negative Head and Neck Cancers

2008 1.1k citations Elizabeth A. Sugar et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Elizabeth A. Sugar United States	38	2.5k	1.4k	1.3k	1.1k	1.0k	113	6.2k
P. Sève France	44	1.2k 0.5×	157 0.1×	611 0.5×	1.0k 1.0×	1.9k 1.9×	280	6.9k
Caroline H. Shiboski United States	29	717 0.3×	721 0.5×	751 0.6×	385 0.4×	402 0.4×	78	5.2k
Christian Grønhøj Denmark	31	1.1k 0.4×	717 0.5×	486 0.4×	1.6k 1.5×	448 0.4×	99	4.6k
Takehiko Mori Japan	40	1.3k 0.5×	178 0.1×	1.2k 0.9×	879 0.8×	497 0.5×	303	5.0k
Douglas A. Arenberg United States	49	4.1k 1.6×	232 0.2×	452 0.3×	3.1k 3.0×	3.0k 2.9×	133	9.5k
Luis F. Fajardo United States	40	1.0k 0.4×	226 0.2×	434 0.3×	541 0.5×	1.4k 1.4×	92	6.9k
George L. Adams United States	40	2.2k 0.9×	3.5k 2.5×	588 0.4×	199 0.2×	2.3k 2.3×	201	7.9k
Jean‐François Bernaudin France	43	1.5k 0.6×	240 0.2×	928 0.7×	731 0.7×	2.0k 2.0×	217	5.5k
G.R. Ogden United Kingdom	34	701 0.3×	1.7k 1.2×	302 0.2×	117 0.1×	405 0.4×	121	4.5k
Reuven Or Israel	44	2.6k 1.0×	148 0.1×	1.4k 1.0×	3.5k 3.3×	972 0.9×	303	10.8k

Countries citing papers authored by Elizabeth A. Sugar

Since Specialization

Citations

This map shows the geographic impact of Elizabeth A. Sugar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elizabeth A. Sugar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elizabeth A. Sugar more than expected).

Fields of papers citing papers by Elizabeth A. Sugar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elizabeth A. Sugar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elizabeth A. Sugar. The network helps show where Elizabeth A. Sugar may publish in the future.

Co-authorship network of co-authors of Elizabeth A. Sugar

This figure shows the co-authorship network connecting the top 25 collaborators of Elizabeth A. Sugar. A scholar is included among the top collaborators of Elizabeth A. Sugar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elizabeth A. Sugar. Elizabeth A. Sugar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jabs, Douglas A., Elizabeth A. Sugar, Alyce Burke, et al.. (2025). Adalimumab versus Conventional Immunosuppression for Uveitis (ADVISE) Trial. Ophthalmology. 133(3). 310–325.

Hill, Colin, Rose Parkinson, Elizabeth M. Jaffee, et al.. (2024). Phase 1 Study of Adjuvant Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor–Transduced Pancreatic Tumor Cell Vaccine, Low-Dose Cyclophosphamide, and Stereotactic Body Radiation Therapy Followed by FOLFIRINOX in High-Risk Resected Pancreatic Ductal Adenocarcinoma. International Journal of Radiation Oncology*Biology*Physics. 121(4). 930–941. 5 indexed citations

Jabs, Douglas A., Elizabeth A. Sugar, Alyce Burke, et al.. (2023). Cataract Surgery in Patients With Uveitis Treated With Systemic Therapy in the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study: Risk Factors and Outcomes. American Journal of Ophthalmology. 254. 210–220. 2 indexed citations

Kaminsky, David A., Robert J. Henderson, Anne E. Dixon, et al.. (2023). Bronchodilator response does not associate with asthma control or symptom burden among patients with poorly controlled asthma. Respiratory Medicine. 218. 107375–107375. 4 indexed citations

Reyfman, Paul A., Elizabeth A. Sugar, Curt J. Reynolds, et al.. (2021). Study protocol for a national cohort of adults focused on respiratory health: the American Lung Association Lung Health Cohort (ALA-LHC) Study. BMJ Open. 11(7). e053342–e053342. 1 indexed citations

Yohannes, Abebaw Mengistu, Michelle N. Eakin, Janet T. Holbrook, et al.. (2020). Association of mild cognitive impairment and characteristic of COPD and overall health status in a cohort study. Expert Review of Respiratory Medicine. 15(1). 153–159. 14 indexed citations

Sugar, Elizabeth A., Alyce Burke, Vidya Venugopal, Jennifer E. Thorne, & Janet T. Holbrook. (2020). Responsiveness of Vision-Specific and General Quality of Life Metrics to Ocular and Systemic Events in Patients with Uveitis. Ophthalmology. 127(12). 1710–1718. 7 indexed citations

Wu, Annie A., Katherine M. Bever, Won Jin Ho, et al.. (2020). A Phase II Study of Allogeneic GM-CSF–Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer. Clinical Cancer Research. 26(19). 5129–5139. 91 indexed citations

Sugar, Elizabeth A., Ana De Jesus‐Acosta, Matthew J. Weiss, et al.. (2018). Diagnostic intervals and pancreatic ductal adenocarcinoma (PDAC) resectability: a single-center retrospective analysis. PubMed. 1. 13–13. 26 indexed citations

10.

Kempen, John H., et al.. (2017). Association Between Long-Lasting Intravitreous Fluocinolone Acetonide Implant vs Systemic Anti-inflammatory Therapy and Visual Acuity at 7 Years Among Patients With Intermediate, Posterior, or Panuveitis. JAMA. 317(19). 1993–1993. 87 indexed citations

11.

Rao, Avani D., Elizabeth A. Sugar, Daniel T. Chang, et al.. (2016). Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cancer. Practical Radiation Oncology. 6(6). 417–424. 16 indexed citations

12.

Wise, Robert A., Janet T. Holbrook, Gerard J. Criner, et al.. (2016). Lack of Effect of Oral Sulforaphane Administration on Nrf2 Expression in COPD: A Randomized, Double-Blind, Placebo Controlled Trial. PLoS ONE. 11(11). e0163716–e0163716. 96 indexed citations

13.

Kempen, John H., Michael M. Altaweel, Lea T. Drye, et al.. (2015). Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis. Ophthalmology. 122(10). 1967–1975. 65 indexed citations

14.

Kempen, John H., Elizabeth A. Sugar, Rohit Varma, et al.. (2014). Risk of Cataract among Subjects with Acquired Immune Deficiency Syndrome Free of Ocular Opportunistic Infections. Ophthalmology. 121(12). 2317–2324. 11 indexed citations

15.

Stearns, Vered, Lisa K. Jacobs, Theodore N. Tsangaris, et al.. (2013). Biomarker Modulation following Short-Term Vorinostat in Women with Newly Diagnosed Primary Breast Cancer. Clinical Cancer Research. 19(14). 4008–4016. 24 indexed citations

16.

Yeo, Charles J., Keith D. Lillemoe, Barbara Biedrzycki, et al.. (2011). A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma. Annals of Surgery. 253(2). 328–335. 295 indexed citations

17.

Dixon, Anne E., Elizabeth A. Sugar, S. James Zinreich, et al.. (2009). Criteria To Screen for Chronic Sinonasal Disease. CHEST Journal. 136(5). 1324–1332. 40 indexed citations

18.

Laheru, Dan, Eric R. Lutz, James M. Burke, et al.. (2008). Allogeneic Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation. Clinical Cancer Research. 14(5). 1455–1463. 259 indexed citations

19.

Hann, Christine L., Vincent C. Daniel, Elizabeth A. Sugar, et al.. (2008). Therapeutic Efficacy of ABT-737, a Selective Inhibitor of BCL-2, in Small Cell Lung Cancer. Cancer Research. 68(7). 2321–2328. 162 indexed citations

20.

Sugar, Elizabeth A., et al.. (2006). Logistic Regression with Exposure Biomarkers and Flexible Measurement Error. Biometrics. 63(1). 143–151. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact